By Scientia Professor Gregory John Dore

Journal articles

Grebely J; Hellard M; Applegate TL; Petoumenos K; Yeung B; Feld J; Rawlinson WD; Lloyd AR; George J; Kaldor JM; Dore GJ; Matthews G; Dolan K, 2012, 'Virological responses during treatment for recent hepatitis C virus: Potential benefit for ribavirin use in HCV/HIV co-infection', AIDS, 26, pp. 1653 - 1661, http://dx.doi.org/10.1097/QAD.0b013e3283553719

Grebely J; Dore GJ, 2012, 'What is killing people with hepatitis C virus infection?', Seminars in Liver Disease, 31, pp. 331 - 339, http://dx.doi.org/10.1055/s-0031-1297922

Matthews GV; Dore GJ, 2011, 'HIV and Hepatitis C Co-Infection', , pp. 177 - 184, http://dx.doi.org/10.1002/9781444346343.ch22

Ewer P; Mills K; Teesson M; Sannibale C; Baker A; Kay-Lambkin F; Dore G, 2011, 'A BRIEF INTERVENTION FOR ALCOHOL AND OTHER DRUG USERS WHO HAVE EXPERIENCED TRAUMA', DRUG AND ALCOHOL REVIEW, 30, pp. 29 - 29, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000297019700088&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Peters L; Neuhaus J; Mocroft A; Soriano V; Rockstroh J; Dore G; Puoti M; Tedaldi E; Clotet B; Kupfer B; Lundgren JD; Klein MB, 2011, 'Hyaluronic acid levels predict increased risk of non-AIDS death in hepatitis-coinfected persons interrupting antiretroviral therapy in the SMART study', Antiviral Therapy, 16, pp. 667 - 675, http://dx.doi.org/10.3851/IMP1815

Sievert W; Dore GJ; Roberts SK, 2011, 'Reply', Hepatology, 53, pp. 1775 - 1776, http://dx.doi.org/10.1002/hep.24250

Matthews GV; Dore GJ, 2011, 'Optimal duration of treatment for acute hepatitis c in human immunodeficiency virus-positive individuals?', Hepatology, 53, pp. 1055 - 1056, http://dx.doi.org/10.1002/hep.24152

Bouchez V; Brun D; Dore G; Njamkepo E; Guiso N, 2011, 'Bordetella parapertussis isolates not expressing pertactin circulating in France', Clinical Microbiology and Infection, 17, pp. 675 - 682, http://dx.doi.org/10.1111/j.1469-0691.2010.03303.x

Grebely J; Matthews G; Hellard M; Shaw D; van Beek I; Petoumenos K; Alavi M; Yeung B; Haber P; Lloyd AR; Kaldor JM; Dore GJ; Dolan K, 2011, 'Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users', Journal of Hepatology, 55, pp. 76 - 85, http://dx.doi.org/10.1016/j.jhep.2010.10.033

Grebely J; Dore GJ, 2011, 'An expanding role for primary care providers in the treatment of hepatitis C virus infection in the community', Hepatology, 54, pp. 2259 - 2261

Sasadeusz J; Dore GJ; Kronborg I; Barton D; Yoshihara M; Weltman M, 2011, 'Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy', Addiction, 106, pp. 977 - 984, http://dx.doi.org/10.1111/j.1360-0443.2010.03347.x

Flynn JK; Dore GJ; Hellard M; Yeung B; Rawlinson WD; White PA; Kaldor JM; Lloyd AR; Ffrench RA; Dolan K, 2011, 'Early IL-10 predominant responses are associated with progression from acute to chronic hepatitis C virus infection in injecting drug users', Journal of Viral Hepatitis, 18, pp. 549 - 561, http://dx.doi.org/10.1111/j.1365-2893.2010.01335.x

Baleriola C; Rawlinson WD; Dore GJ; Chaverot S; Stelzer-Braid S; Yoshihara M; Crawford D; Sievert W; McCaughan G; Weltman M; Cheng W; Rizkalla B; Dubois D; Thommes J; Roberts S, 2011, 'Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients', Antiviral Therapy, 16, pp. 173 - 180, http://dx.doi.org/10.3851/IMP1731

Audsley J; Seaberg E; Sasadcusz J; Matthews G; Avihingsanon A; Ruxrungtham K; Fairley K; Finlayson RJ; Hwang H; Littlejohn M; Locarnini S; Dore GJ; Thio C; Lewin S, 2011, 'Factors associated with elevated ALT in an international HIV/HBV Co-Infected cohort on long-term HAART', PLoS One, 6, pp. e26482, http://dx.doi.org/10.1371/journal.pone.0026482

Grebely J; Bryant J; Hull PB; Hopwood MN; Lavis YM; Dore GJ; Treloar C, 2011, 'Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia.', Journal of Viral Hepatitis, 18, pp. 104 - 116, http://dx.doi.org/10.1111/j.1365

Dore GJ; Matthews GV; Rockstroh J, 2011, 'Future of hepatitis C therapy: Development of direct-acting antivirals', Current opinion in HIV & AIDS, 6, pp. 508 - 513, http://dx.doi.org/10.1097/COH.0b013e32834b87f8

Grebely J; Dore GJ, 2011, 'Hepatitis C: Enhancing treatment for hepatitis C among drug users', Nature Reviews Gastroenterology and Hepatology, 8, pp. 11 - 13, http://dx.doi.org/10.1038/nrgastro.2010.186

Gidding HF; Amin J; Dore GJ; Law MG, 2011, 'Hospitalization rates associated with hepatitis B and HIV co-infection, age and sex in a population-based cohort of people diagnosed with hepatitis C', Epidemiology and Infection, 139, pp. 1151 - 1158

Smith KR; Suppiah V; O''Connor K; Berg T; Weltman M; Abate ML; Spengler U; Bassendine M; Matthews G; Irving W; Powell E; Riordan S; Ahlensteil G; Stewart GJ; Bahlo M; Booth DR; George J, 2011, 'Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort', Genome Medicine, 3, pp. 57

Suppiah V; Gaudieri S; Armstrong N; O''connor K; Berg T; Weltman M; Abate M; Spengler U; Bassendine M; Dore G; Irving W; Powell E; Hellard M; Riordan S; Mathews G; Sheridan D; Natterman J; Smedile A; Muller T; Hammond E; Dunn D; Negro F; Bochud Y; Mallal S; Ahlenstiel G; Stewart G; George J; Booth D, 2011, 'IL28B, HLA-C and KIR variants additively and interactively predict response to therapy in chronic hepatitis C virus infection', PLOS Medicine, 8, pp. e1001092, http://dx.doi.org/10.1371/journal.pmed.1001092

Suppiah V; Gaudieri S; Armstrong NJ; O''Connor KS; Berg T; Weltman M; Abate ML; Spengler U; Bassendine M; Dore GJ; Irving WL; Powell E; Hellard M; Riordan S; Matthews G; Sheridan D; Nattermann J; Smedile A; Muller T; Hammond E; Dunn ; Negro F; Bochud PY; Mallal SA; Ahlenstiel G; Stewart GJ; George J; Booth DR, 2011, 'IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: A cross-sectional study.', PLOS Medicine, 8, pp. e1001092

Grebely J; Raffa JD; Lai C; Kerr T; Fischer B; Krajden M; Dore GJ; Tyndall MW, 2011, 'Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents', Journal of Viral Hepatitis, 18, pp. 32 - 41, http://dx.doi.org/10.1111/j.1365-2893.2010.01279.x

Matthews G; Pham STP; Hellard M; Grebely J; Zhang L; Oon A; Marks P; Van Beek IA; Rawlinson WD; Kaldor JM; Lloyd AR; Dore GJ; White PA, 2011, 'Patterns and characteristics of Hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian Trial in Acute Hepatitis C', Clinical Infectious Diseases, 52, pp. 803 - 811, http://dx.doi.org/10.1093/cid/ciq200

Gidding HF; Law MG; Amin J; MacDonald GJ; Sasadeusz JJ; Jones TL; Strasser SI; George J; Dore GJ, 2011, 'Predictors of deferral of treatment for hepatitis C infection in Australian clinics', The Medical Journal of Australia, 194, pp. 398 - 402

Grebely J; Dore GJ, 2011, 'Prevention of hepatitis C virus in injecting drug users: A narrow window of opportunity', Journal of Infectious Diseases, 203, pp. 571 - 574

Walter SR; Thein H; Gidding HF; Amin J; George J; Dore GJ, 2011, 'Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C', Journal of Gastroenterology and Hepatology (JGH), 26, pp. 1757 - 1764, http://dx.doi.org/10.1111/j.1440-1746.2011.06785.x

Bull RA; Luciani F; McElroy K; Gaudieri S; Pham ST; Chopra A; Cameron B; Maher L; Dore GJ; White PA; Lloyd AR, 2011, 'Sequential Bottlenecks Drive Viral Evolution in Early Acute Hepatitis C Virus Infection', PLoS Pathog, 7, pp. e1002243, http://dx.doi.org/10.1371/journal.ppat.1002243

Grebely J; Matthews G; Dore GJ, 2011, 'Treatment of acute HCV infection', Nature Reviews Gastroenterology and Hepatology, 8, pp. 265 - 274, http://dx.doi.org/10.1038/nrgastro.2011.32

Gidding HF; Dore GJ; Amin J; Law MG, 2011, 'Trends in all cause and viral liver disease-related hospitalizations in people with hepatitis B or C: a population-based linkage study', BMC Public Health, 11, pp. 52

Thein HH; Walter SR; Gidding HF; Amin J; Law MG; George J; Dore GJ, 2011, 'Trends in incidence of hepatocellular carcinoma after diagnosis of hepatitis B or C infection: A population-based cohort study, 1992-2007', Journal of Viral Hepatitis, 18, pp. e232 - e241, http://dx.doi.org/10.1111/j.1365-2893.2011.01440.x

Walter SR; Thein HH; Amin J; Gidding HF; Ward K; Law MG; George J; Dore GJ, 2011, 'Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006', Journal of Hepatology, 54, pp. 879 - 886, http://dx.doi.org/10.1016/j.jhep.2010.08.035

Sievert W; Dore GJ; McCaughan GW; Yoshihara M; Crawford D; Cheng W; Weltman M; Rawlinson W; Rizkalla B; DePamphilis JK; Roberts SK, 2011, 'Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1', Hepatology, 53, pp. 1109 - 1117, http://dx.doi.org/10.1002/hep.24180

Grebely J; Dore GJ, 2011, 'What is killing people with HCV infection?', Seminars in Liver Disease, 31, pp. 331 - 339

Grebely J; Matthews GV; Petoumenos K; Dore GJ, 2010, 'Spontaneous clearance and the beneficial impact of treatment on clearance during recent hepatitis C virus infection', Journal of Viral Hepatitis, 17, pp. 896, http://dx.doi.org/10.1111/j.1365-2893.2009.01256.x

Dore G; Grebely J; Gillman A; Thein R; Day C; Ryan L; Treloar C; Haber P, 2010, 'PRESENTER 1: OVERVIEW OF TREATMENT OF HEPATITIS C (HCV) IN THE OPIATE PHARMACOTHERAPY SETTING AND THE ENHANCING TREATMENT OF HEPATITIS C IN THE OPIATE SUBSTITUTION SETTING (ETHOS) PARTNERSHIP INITIATIVE', DRUG AND ALCOHOL REVIEW, 29, pp. 21 - 21, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000284895600048&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Grebely J; Bryant J; Hull P; Hopwood M; Dore G; Treloar C, 2010, 'PRESENTER 2: SPECIALIST ASSESSMENT AND TREATMENT OF HEPATITIS C VIRUS INFECTION AMONG INJECTION DRUG USERS IN NEW SOUTH WALES, AUSTRALIA', DRUG AND ALCOHOL REVIEW, 29, pp. 21 - 21, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000284895600049&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Grebely J; Petoumenos K; Matthews G; Haber PS; Marks P; Lloyd AROLA; Kaldor JM; Dore GJ; Hellard M; Dolan K, 2010, 'Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study', Drug and Alcohol Dependence, 107, pp. 244 - 249, http://dx.doi.org/10.1016/j.drugalcdep.2009.09.015

Milner K; van der Poorten D; Trenell M; Jenkins AB; Xu A; Smythe GA; Dore GJ; Zekry A; Weltman MD; Fragomeli V; George J; Chisholm DJ, 2010, 'Chronic Hepatitis C is associated with peripheral rather than hepatic insulin resistance', Gastroenterology, 138, pp. 932 - 941

Dore GJ; Hellard M; Matthews G; Grebely J; Haber PS; Petoumenos K; Yeung B; Marks P; Van Beek IA; McCaughan G; White PA; French R; Rawlinson WD; Lloyd AROLA; Kaldor JM; Dolan K, 2010, 'Effective treatment of injecting drug users with recently acquired hepatitis C virus infection', Gastroenterology, 138, pp. 123 - 135, http://dx.doi.org/10.1053/j.gastro.2009.09.019

Avihingsanon A; Lewin S; Kerr SJ; Chang JJ; Piyawat K; Napissanant N; Matthews G; Dore GJ; Bowden S; Lange J; Ruxrungtham K, 2010, 'Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naïve HIV-HBV coninfection in Thailand', Antiviral Therapy, 15, pp. 917 - 922

Dore GJ; Soriano V; Rockstroh J; Kupfer B; Tedaldi E; Peters L; Neuhaus J; Puoti M; Klein M; Mocroft A; Clotet B; Lundgren JD, 2010, 'Frequent hepatitis B virus rebound among HIV–hepatitis B virus-coinfected patients following antiretroviral therapy interruption', AIDS, 24, pp. 857 - 865

Pham STP; Bull RA; Bennett JM; Rawlinson WD; Lloyd AR; Dore GJD; White PA; Bull , 2010, 'Frequent multiple hepatitis C virus infections among injection drug users in a prison setting', Hepatology, 52, pp. 1564 - 1572, http://dx.doi.org/10.1002/hep.23885

Audsley J; Yuen L; Littlejohn M; Sasadcusz J; Ayres A; Desmond C; Spelman T; Lau GT; Matthews G; Avihingsanon A; Seaberg E; Philp F; Saulynas M; Ruxrungtham K; Dore GJ; Locarnini S; Thio C; Lewin S; Revill P, 2010, 'HBV mutations in untreated HIV-HBV co-infection using genomic length sequencing', Virology, 405, pp. 539 - 547, http://dx.doi.org/10.1016/j.virol.2010.06.038

Day C; White B; Dore G; Van Beek I; Rodgers C; Cunningham P; Wodak A; Maher L, 2010, 'Hepatitis B virus among injecting drug users in Sydney, Australia: Prevalence, vaccination and knowledge of status', Drug and Alcohol Dependence, 108, pp. 134 - 137, http://dx.doi.org/10.1016/j.drugalcdep.2009.11.013

Gidding HF; Amin J; Dore GJ; Ward K; Law MG, 2010, 'Hospital-related morbidity in people notified with hepatitis C: A population-based record linkage study in New South Wales, Australia', Journal of Hepatology, 53, pp. 43 - 49

Teutsch S; Luciani F; Scheuer N; McCredie L; Hosseiny P; Rawlinson WD; Kaldor JM; Dore GJ; Dolan K; Ffrench R; Lloyd AROLA; Haber P; Levy MH, 2010, 'Incidence of primary Hepatitis C infection and risk factors for transmission in an Australian prisoner cohort', BMC Public Health, 10, pp. 1 - 9, http://dx.doi.org/10.1186/1471-2458-10-633

Cheng W; Roberts S; McCaughan G; Sievert W; Weltman MD; Crawford D; Rawlinson WD; Marks P; Thommes J; Rizkalla B; Yoshihara M; Dore GJ, 2010, 'Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing', Journal of Hepatology, 53, pp. 616 - 623

Crane M; Sirivichayakul S; Chang JJ; Avihingsanon A; Ubolyam S; Buranapraditkun S; Thantiworasit P; Wightman F; Locarnini S; Matthews G; Dore GJ; Ruxrungtham K; Lewin SR, 2010, 'No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy', Journal of Virology, 84, pp. 2657 - 2665

Grebely J; Petoumenos K; Hellard M; Matthews G; Suppiah V; Applegate TL; Yeung B; Marks P; Rawlinson WD; Lloyd AROLA; Booth D; Kaldor JM; George J; Dore GJ; Amin J; Cameron B; Acraman B; Dolan K; Bloch M; Van Beek I; Li H; Madden A, 2010, 'Potential Role for Interleukin-28B Genotype in Treatment Decision-Making in Recent Hepatitis C Virus Infection', Hepatology, 52, pp. 1216 - 1224, http://dx.doi.org/10.1002/hep.23850

Grebely J; Knight E; Ngai T; Genoway K; Raffa J; Storms M; Gallagher L; Krajden M; Dore GJ; Duncan F; Conway B, 2010, 'Reinfection with hepatitis C virus following sustained virological response in injection drug users', Journal of Gastroenterology and Hepatology, 25, pp. 1281 - 1284, http://dx.doi.org/10.1111/j.1440-1746.2010.06238.x

Back to profile page